← Back to headlines
Bristol-Myers Squibb's $14 Billion Neuroscience Drug Bet Disappoints
Bristol-Myers Squibb's significant $14 billion investment in a neuroscience drug has reportedly turned into an early letdown, indicating potential setbacks for the pharmaceutical giant's venture.
28 Apr, 09:00 — 28 Apr, 09:00
Sources
Showing 1 of 1 sources
